AU723262B2 - Peptide and O-glycan inhibitors of selectin mediated inflammation - Google Patents

Peptide and O-glycan inhibitors of selectin mediated inflammation Download PDF

Info

Publication number
AU723262B2
AU723262B2 AU67669/96A AU6766996A AU723262B2 AU 723262 B2 AU723262 B2 AU 723262B2 AU 67669/96 A AU67669/96 A AU 67669/96A AU 6766996 A AU6766996 A AU 6766996A AU 723262 B2 AU723262 B2 AU 723262B2
Authority
AU
Australia
Prior art keywords
psgl
glycans
selectin
cells
glycan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU67669/96A
Other languages
English (en)
Other versions
AU6766996A (en
Inventor
Richard D. Cummings
Rodger P Mcever
Kevin L Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oklahoma filed Critical University of Oklahoma
Publication of AU6766996A publication Critical patent/AU6766996A/en
Application granted granted Critical
Publication of AU723262B2 publication Critical patent/AU723262B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU67669/96A 1995-08-03 1996-08-02 Peptide and O-glycan inhibitors of selectin mediated inflammation Ceased AU723262B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US51092095A 1995-08-03 1995-08-03
US08/510920 1995-08-03
US1779496P 1996-05-15 1996-05-15
US60/017794 1996-05-15
US64980296A 1996-05-17 1996-05-17
US08/649802 1996-05-17
PCT/US1996/012820 WO1997006176A2 (en) 1995-08-03 1996-08-02 Peptide and o-glycan inhibitors of selectin mediated inflammation

Publications (2)

Publication Number Publication Date
AU6766996A AU6766996A (en) 1997-03-05
AU723262B2 true AU723262B2 (en) 2000-08-24

Family

ID=27360885

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67669/96A Ceased AU723262B2 (en) 1995-08-03 1996-08-02 Peptide and O-glycan inhibitors of selectin mediated inflammation

Country Status (11)

Country Link
EP (1) EP0850243B1 (2)
JP (1) JPH11510543A (2)
KR (1) KR100523506B1 (2)
AT (1) ATE251636T1 (2)
AU (1) AU723262B2 (2)
CA (1) CA2228512A1 (2)
DE (1) DE69630307T2 (2)
DK (1) DK0850243T3 (2)
ES (1) ES2208759T3 (2)
MX (1) MXPA98000968A (2)
WO (1) WO1997006176A2 (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
DE69934890D1 (de) 1998-06-16 2007-03-08 Univ Oklahoma Glykosulfopeptide und verfahren zu deren herstellung und deren verwendung
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US20030143662A1 (en) 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
MXPA01004310A (es) * 1998-10-30 2003-06-06 Cbr Lab Inc Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl).
CA2347940A1 (en) * 1998-11-21 2000-06-02 The Regents Of The University Of California Use of core 2 glcnac transferase inhibitors in treating inflammation
US6492152B1 (en) 1999-06-15 2002-12-10 The Board Of Regents Of The University Of Oklahoma Core 1 β3-galactosyl transferases and methods of use thereof
US7256171B1 (en) 1999-11-20 2007-08-14 The Regents Of The University Of California Use of core 2 G1cNAc transferase inhibitors in treating inflammation
EP1325123A4 (en) * 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
CA2433225A1 (en) * 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
WO2004012817A2 (en) * 2002-07-31 2004-02-12 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
JP4599027B2 (ja) * 2002-10-30 2010-12-15 東洋水産株式会社 Ｌ−セレクチン結合阻害剤
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
CN1985000B (zh) 2004-05-11 2012-05-30 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
JP5331293B2 (ja) * 2006-04-28 2013-10-30 公益財団法人野口研究所 多様性を表現するオリゴ糖またはその誘導体
CN108947375B (zh) * 2008-09-02 2022-02-22 建筑研究和技术有限公司 包含增塑剂的硬化加速剂组合物
WO2011047794A2 (en) * 2009-10-21 2011-04-28 Eth Zurich Medical utility of glycan-binding proteins and glycans
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
KR102715540B1 (ko) 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668907A1 (en) * 1992-11-16 1995-08-30 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
WO1995030001A2 (en) * 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein

Also Published As

Publication number Publication date
WO1997006176A2 (en) 1997-02-20
KR100523506B1 (en) 2005-10-24
KR20040039440A (ko) 2004-05-10
AU6766996A (en) 1997-03-05
CA2228512A1 (en) 1997-02-20
WO1997006176A3 (en) 1997-07-24
DK0850243T3 (da) 2004-02-02
ES2208759T3 (es) 2004-06-16
ATE251636T1 (de) 2003-10-15
MXPA98000968A (es) 2002-07-15
EP0850243B1 (en) 2003-10-08
DE69630307D1 (de) 2003-11-13
JPH11510543A (ja) 1999-09-14
EP0850243A2 (en) 1998-07-01
DE69630307T2 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
AU723262B2 (en) Peptide and O-glycan inhibitors of selectin mediated inflammation
US6124267A (en) O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
Suzuki et al. Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen
Li et al. Post-translational Modifications of Recombinant P-selectin Glycoprotein Ligand-1 Required for Binding to P-and E-selectin (∗)
Moore et al. The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine.
Kumar et al. Core2 beta-1, 6-N-acetylglucosaminyltransferase enzyme activity is critical for P-selectin glycoprotein ligand-1 binding to P-selectin
EP0730608B1 (en) Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5464778A (en) Glycoprotein ligand for P-selectin and methods of use thereof
AU660627B2 (en) Functionally active selectin-derived peptide for GMP-140
Sako et al. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding
US6667036B2 (en) Methods of treatment using antibodies to P-selectin glycoprotein ligand
CA2151142C (en) Glycoprotein ligand for p-selectin and methods of use thereof
CZ96893A3 (en) Inhibition of adhesive protein cells and their carbohydrates interaction
IE913722A1 (en) Agents and methods for binding to elam-1
Stoolman Selectins (LEC-CAMs): lectin-like receptors involved in lymphocyte recirculation and leukocyte recruitment
EP1428832A2 (en) Peptide and O-glycan inhibitors of selectin mediated inflammation
KR100463567B1 (ko) 셀렉틴매개염증의펩티드및0-글리칸억제제
HK1066813A (en) Peptide and o-glycan inhibitors of selectin mediated inflammation
Irimura Molecular Cloning and Expression of cDNA Encoding Human Macrophage C-Type Lectin
Stoolman SELECTINS (LEC-CAMs): LECTIN-LIKE RECEPTORS
Sassetti The CD34 family
EP1245575A2 (en) Functionally active selectin-derived peptides and ligand for GMP140
Wilkins The post-translational modifications of PSGL-1 required for high-affinity binding to P-selectin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)